General Anxiety Disorder Market reach USD 3,775 million in 2020 , Globally

Zion Market Research has published a new report titled “General Anxiety Disorder Market by Therapeutics (Antidepressant, Benzodiazepines and Others): U.S. Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020.” According to the report, The U.S. demand for general anxiety disorder market was valued at USD 3,251 million in 2014, and is expected to generate revenue of USD 3,775 million by end of 2020, growing at a CAGR of 2.4% between 2015 and 2020.

Request Sample Report: http://www.zionmarketresearch.com/sample/general-anxiety-disorder-market

General anxiety disorders or generalized anxiety disorders (GAD) usually happen along with other physical or mental illnesses such as alcohol or substance abuse, which might mask anxiety symptoms. In some scenario, these other illnesses treated prior to person respond to treatment for the anxiety disorder. Efficient therapies for general anxiety disorders are present, and ongoing research is uncovering novel treatments that may aid most people with GAD.

Currently, U.S. general anxiety disorders market is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Presently, general anxiety disorders market is on a decline owing to weak pipeline of novel drugs, patent expiry of major antidepressants and increasing number of cheap generic drug variants in the market. U.S. stands for the major regional market for anxiety disorder therapeutics worldwide.

Do Inquiry before buying: http://www.zionmarketresearch.com/inquiry/general-anxiety-disorder-market

General anxiety disorder market includes several types of therapeutic segments such as antidepressant, benzodiazepines and other therapeutics. Antidepressant was a main therapeutic segment of general anxiety disorder market and accounted 38.6% share of the total demand in 2014. This segment is further expected to continue its dominance in market over the estimate period. Several kinds of medications employed to treat general anxiety disorder. Antidepressants such as serotonin norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake inhibitor (SSRI) classes, are the first-line medication treatments. Benzodiazepines are the most common class of anti anxiety drugs and usually employed only for relieving severe anxiety on a short-term basis. These are medications alleviate anxiety by slowing down the central nervous system. Their calming and relaxing effects have made them very popular in U.S. They are also prescribed as muscle relaxants and sleeping pills.

North America emerged as foremost regional market for the global depression in 2014. This was mostly due to presence of large population infected with many kinds of depression and anxiety disorders. Some of the renowned players in this market include Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of dominant players in the market space.

Browse detail report at: http://www.zionmarketresearch.com/report/general-anxiety-disorder-market

The report segments the U.S. general anxiety disorder market into:

U.S. General anxiety disorder Market: Therapeutics Segment Analysis
• Antidepressant
• Benzodiazepines
• Others (Buspirone)

About Us:
Zion Market Research is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Zion Market Research is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading industry and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:
Zion Market Research
4283, Express Lane,
Suite 634-143,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: http://www.zionmarketresearch.com

This release was published on openPR.